Affimed (AFMD) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Affimed (NASDAQ:AFMD) from a hold rating to a buy rating in a research note released on Wednesday morning. Zacks Investment Research currently has $2.25 price objective on the biopharmaceutical company’s stock.

According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “

How to Become a New Pot Stock Millionaire

NASDAQ:AFMD opened at $2.10 on Wednesday. The company has a quick ratio of 5.58, a current ratio of 5.61 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $131.02, a price-to-earnings ratio of -2.69 and a beta of 2.30. Affimed has a 12 month low of $1.15 and a 12 month high of $2.85.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Tuesday, March 20th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.56 million. Affimed had a negative net margin of 1,493.69% and a negative return on equity of 80.04%. research analysts anticipate that Affimed will post -0.65 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC lifted its stake in shares of Affimed by 483.0% in the fourth quarter. Virtu Financial LLC now owns 85,562 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 70,886 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of Affimed in the fourth quarter valued at $136,000. Dimensional Fund Advisors LP lifted its stake in shares of Affimed by 817.9% in the third quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 122,773 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Affimed in the third quarter valued at $658,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3338264/affimed-afmd-lifted-to-buy-at-zacks-investment-research.html.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

PS Business Parks  Scheduled to Post Quarterly Earnings on Monday
PS Business Parks Scheduled to Post Quarterly Earnings on Monday
American National Ins  Scheduled to Post Earnings on Monday
American National Ins Scheduled to Post Earnings on Monday
Arch Capital Group  Set to Announce Quarterly Earnings on Monday
Arch Capital Group Set to Announce Quarterly Earnings on Monday
New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.